Continuation of Anti-osteoporotic Treatment 1 Year After Initial Administration (POUROSTEO)

Grenoble Alpes University Hospital Center (CHU)

Status: Not yet enrolling

Conditions: Osteoporosis Fracture

Treatments: Other: phone survey

Study type: Observational

Funder types: Other

Identifiers

NCT06024148

38RC23.0179

Details and patient eligibility

About

The aim of this observational study is to assess the obstacles and levers to the continuation of anti-osteoporotic treatment, and to identify those where action could be taken to improve the quality of care for fractured patients.

The individual and collective stakes are high. Fracture is the most feared complication of osteoporosis. The current under-diagnosis and under-treatment of this chronic pathology exposes patients to a high risk of early re-fracture, with the associated morbidity and mortality.

General practitioners have a major role to play in monitoring and coordinating patients' healthcare pathways. The aim of this study is to assess ways of improving osteoporosis management in order to improve quality of life and disability-free life expectancy for individual patients. The public health and economic stakes are equally high. It is by identifying the obstacles that prospective work on the key elements to be implemented could help optimize osteoporosis management.

Full description

Selection of patients hospitalized at the Rocheplane Medical Center between June 2021 and May 2022, following a severe osteoporotic fracture and having received a first dose of antiosteoporotic treatment during their overall stay (initial admission department + CMR).

Sending of an information letter and request for non-objection from patients or their trusted support person, with a 1-month cooling-off period to express opposition.

Collection of variables of interest from CMR patients' medical records, followed by administration of a telephone hetero-questionnaire (transferred to Excel) to patients or their families 1 year after fracture occurrence.

If the patient or family did not answer the questionnaire, or if it was incomplete (missing data), the information could be sought by telephone from the attending physician.

Enrollment: 250 estimated patients

Sex: All

Ages: 75+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hospitalization in CMR's Geriatric Rehabilitation Department between 01/06/2021 and 31/05/2022
• Age: 75 and over
• Admitted with severe post-fracture osteoporosis
• Having received a first dose of antiosteoporotic treatment between the day the fracture occurred and discharge from CMR (either in an inpatient unit prior to CMR, or at CMR)

Exclusion criteria

• Having objected to the use of his/her data for research purposes
• Subject under guardianship or deprived of liberty.
• Pathological fracture
• Anti-osteoporotic treatment prior to fracture
• 1-year follow-up made impossible by lack of contact with patient, family or attending physician.

Trial design

250 participants in 1 patient group

patients hospitalized in the Geriatric Rehabilitation Department

Description:

patients aged 75 and over, admitted with a severe osteoporotic post-fracture, having received a first dose of antiosteoporotic treatment between the day of fracture and discharge from Geriatric Rehabilitation Department

Treatment:

Other: phone survey